Terms: = Leukemia AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Diagnosis
10 results:
1. Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
Panelli P; De Santis E; Colucci M; Tamiro F; Sansico F; Miroballo M; Murgo E; Padovano C; Gusscott S; Ciavarella M; Chavez EA; Bianchi F; Rossi G; Carella AM; Steidl C; Weng AP; Giambra V
Blood; 2023 Mar; 141(13):1597-1609. PubMed ID: 36315912
[TBL] [Abstract] [Full Text] [Related]
2. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
Aggoune D; Sorel N; Bonnet ML; Goujon JM; Tarte K; Hérault O; Domenech J; Réa D; Legros L; Johnson-Ansa H; Rousselot P; Cayssials E; Guerci-Bresler A; Bennaceur-Griscelli A; Chomel JC; Turhan AG
Leuk Res; 2017 Sep; 60():94-102. PubMed ID: 28772207
[TBL] [Abstract] [Full Text] [Related]
3. foxo3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL.
Consolaro F; Ghaem-Maghami S; Bortolozzi R; Zona S; Khongkow M; Basso G; Viola G; Lam EW
Mol Cancer Res; 2015 Dec; 13(12):1578-90. PubMed ID: 26376801
[TBL] [Abstract] [Full Text] [Related]
4. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
[TBL] [Abstract] [Full Text] [Related]
5. [Expression of foxo3a in patients with acute myeloid leukemia and its clinical significance].
Zhao JN; Lu QY; Niu XQ; Zhang P; Wang Z; Lin JZ; Zhuang YH; Lu JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):847-50. PubMed ID: 23998572
[TBL] [Abstract] [Full Text] [Related]
6. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
Avet-Loiseau H; Durie BG; Cavo M; Attal M; Gutierrez N; Haessler J; Goldschmidt H; Hajek R; Lee JH; Sezer O; Barlogie B; Crowley J; Fonseca R; Testoni N; Ross F; Rajkumar SV; Sonneveld P; Lahuerta J; Moreau P; Morgan G;
Leukemia; 2013 Mar; 27(3):711-7. PubMed ID: 23032723
[TBL] [Abstract] [Full Text] [Related]
7. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.
Han BW; Feng DD; Li ZG; Luo XQ; Zhang H; Li XJ; Zhang XJ; Zheng LL; Zeng CW; Lin KY; Zhang P; Xu L; Chen YQ
Hum Mol Genet; 2011 Dec; 20(24):4903-15. PubMed ID: 21926415
[TBL] [Abstract] [Full Text] [Related]
8. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Dewar R; Chen ST; Yeckes-Rodin H; Miller K; Khosravi-Far R
Cancer Biol Ther; 2011 Mar; 11(6):552-8. PubMed ID: 21282974
[TBL] [Abstract] [Full Text] [Related]
9. Highly phosphorylated foxo3A is an adverse prognostic factor in acute myeloid leukemia.
Kornblau SM; Singh N; Qiu Y; Chen W; Zhang N; Coombes KR
Clin Cancer Res; 2010 Mar; 16(6):1865-74. PubMed ID: 20215543
[TBL] [Abstract] [Full Text] [Related]
10. Covert preleukemia driven by MLL gene fusion.
Zuna J; Burjanivova T; Mejstrikova E; Zemanova Z; Muzikova K; Meyer C; Horsley SW; Kearney L; Colman S; Ptoszkova H; Marschalek R; Hrusak O; Stary J; Greaves M; Trka J
Genes Chromosomes Cancer; 2009 Jan; 48(1):98-107. PubMed ID: 18932267
[TBL] [Abstract] [Full Text] [Related]
